LY-404,187

LY-404,187 is a pharmacological agent that belongs to the class of AMPAR potentiators. It is an ampakine compound that has been developed by Eli Lilly and Company, a multinational pharmaceutical company. LY-404,187 is known for its potential therapeutic applications in the treatment of various neurological disorders, including schizophrenia, depression, and Alzheimer's disease.

Pharmacology[edit | edit source]

LY-404,187 is an AMPAR potentiator, which means it enhances the activity of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), a type of ionotropic glutamate receptor. AMPARs are involved in fast synaptic transmission in the central nervous system (CNS). The potentiating effect of LY-404,187 on AMPARs is believed to improve neurotransmission and cognitive function.

Therapeutic Applications[edit | edit source]

LY-404,187 has been studied for its potential use in the treatment of several neurological disorders.

Schizophrenia[edit | edit source]

In schizophrenia, LY-404,187 may help to alleviate cognitive deficits associated with the disorder. This is due to its ability to potentiate AMPARs, which are thought to be hypoactive in individuals with schizophrenia.

Depression[edit | edit source]

LY-404,187 may also have potential as a treatment for depression. Studies have suggested that AMPAR potentiators can enhance the efficacy of antidepressants, potentially leading to improved treatment outcomes.

Alzheimer's Disease[edit | edit source]

In Alzheimer's disease, LY-404,187 may help to improve cognitive function and slow disease progression. This is due to its ability to enhance glutamatergic neurotransmission, which is often impaired in Alzheimer's disease.

Safety and Tolerability[edit | edit source]

Like all pharmacological agents, LY-404,187 has the potential to cause side effects. However, in preclinical studies, it has been shown to be well-tolerated, with a favorable safety profile.